ADVERSE EFFECTS AFTER VACCINATION AGAINST SARS-COV-2 (COVID-19) IN DOWN SYNDROME ADULTS.

Introduction: Comorbidities in adults with Down syndrome are common making them a risk group for COVID-19. Thus, vaccinating against COVID-19 becomes necessary, but requires care against possible side effects. Objective: To investigate possible adverse effects after vaccination against COVID-19 in a...

Descripción completa

Detalles Bibliográficos
Publicado en:ConScientiae Saúde Vol. 22; no. 1; pp. 1 - 10
Autores principales: Lacerda de Andrade, Michele, Uehara, Laura, Ferreira de Moraes, Janaina, Ferrari Corrêa, João Carlos, Corrêa, Fernanda Ishida
Formato: research tables/charts Journal Article
Publicado: Nove de Julho University 2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=176239348&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 176239348
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        16771028
        B0TO
      jtl: ConScientiae Saúde
      issn: 16771028
      maglogo: N
    pubinfo:
      dt: 2023
      vid: 22
      iid: 1
      pid: 59221
      pub: Nove de Julho University
    artinfo:
      ui:
        176239348
        176239348
        176239348
        10.5585/22.2023.23794
        176239348
      ppf: 1
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: ADVERSE EFFECTS AFTER VACCINATION AGAINST SARS-COV-2 (COVID-19) IN DOWN SYNDROME ADULTS.
      aug:
        au:
          Lacerda de Andrade, Michele
          Uehara, Laura
          Ferreira de Moraes, Janaina
          Ferrari Corrêa, João Carlos
          Corrêa, Fernanda Ishida
        affil: Master, Doctoral and Master's Rehabilitation Science Programs, Nove de Julho University, São Paulo/SP, São Paulo, 01504-001, Brazil
      sug:
        subj:
          Adverse Health Care Event
          Immunization
          SARS-CoV-2
          Down Syndrome In Adulthood
          Human
          Adult
          Descriptive Research
          Questionnaires
          Fever
          Muscle Pain
          Interviews
          Adult: 19-44 years
      ab:
        Introduction: Comorbidities in adults with Down syndrome are common making them a risk group for COVID-19. Thus, vaccinating against COVID-19 becomes necessary, but requires care against possible side effects. Objective: To investigate possible adverse effects after vaccination against COVID-19 in adults with Down Syndrome (DS). Methodology: Descriptive study in which ninety-seven adults diagnosed with DS were interviewed using a questionnaire containing seventeen questions related to personal and historical data, and seven questions related to vaccination. Results: The most applied vaccine was AstraZeneca (94%), Pfizer (4%), and CoronaVac (2%); 74% of the subjects had adverse effects, the most frequent after the first dose being pain at the injection site (65.3%), fever (37.9%), muscle pain (37.8%), malaise (29.5%); in the second dose there was a decrease in these adverse effects; 95% of symptoms disappeared after the first 24 hours following application. Conclusion: More than half of the individuals interviewed had adverse effects after the application of the first dose of the vaccine, decreasing with the second dose; the most frequent was pain at the site of application.
        Introdução: Comorbidades em adultos com síndrome de Down são comuns tornando-os um grupo de risco para COVID-19. Dessa forma, vacinar contra a COVID-19 torna-se necessária, mas requer cuidados contra possíveis efeitos colaterais. Objetivo: Pesquisar possíveis efeitos adversos após vacinação contra COVID- 19 em adultos com Síndrome de Down (SD). Metodologia: Estudo descritivo no qual 97 adultos diagnosticados com SD foram entrevistados por meio de um questionário contendo dezessete questões relacionadas a dados pessoais e histórico, e sete questões relacionadas à vacinação. Resultados: A vacina mais aplicada foi a AstraZeneca (94%), Pfizer (4%) e CoronaVac (2%); 74% dos sujeitos apresentaram efeitos adversos, sendo os mais frequentes após a primeira dose: dor no local da injeção (65,3%), febre (37,9%), dores musculares (37,8%), mal-estar (29,5%); na segunda dose houve diminuição desses efeitos adversos; 95% dos sintomas desapareceram após as primeiras 24 horas após a aplicação. Conclusão: Mais da metade dos indivíduos entrevistados apresentou efeitos adversos após a aplicação da primeira dose da vacina, diminuindo com a segunda dose; a mais frequente foi a dor no local de aplicação.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N